Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$1.28 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Biofrontera Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 28 | 25 | 8 | -99,999 |
Receivables | 5 | 7 | 12 | 3 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 11 | 7 | 4 | 7 | NA |
Other Current Assets | 6 | 1 | 5 | 1 | NA |
Total Current Assets | 23 | 43 | 46 | 20 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 3 | 3 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 3 | 3 | 3 | 4 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 28 | 51 | 53 | 24 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 9 | 3 | 1 | 2 | NA |
Current Portion Long-Term Debt | 4 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 4 | 11 | 10 | 3 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 7 | 3 | 0 | NA |
Total Current Liabilities | 18 | 21 | 14 | 4 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 4 | 5 | 28 | 14 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 23 | 27 | 42 | 18 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 104 | 103 | 90 | 47 | NA |
Retained Earnings | -100 | -80 | -79 | -41 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 5 | 24 | 11 | 6 | NA |
Total Liabilities & Shareholder's Equity | 28 | 51 | 53 | 24 | NA |
Total Common Equity | 5 | 24 | 11 | 6 | 0 |
Shares Outstanding | 1.50 | 1.30 | 0.80 | NA | NA |
Book Value Per Share | 3.19 | 18.37 | 14.18 | 0.00 | 0.00 |
Fiscal Year End for Biofrontera Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 4 | 1 | 7 | 10 |
Receivables | 4 | 4 | 5 | 7 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 7 | 11 | 16 | 15 |
Other Current Assets | 6 | 6 | 6 | 0 | 1 |
Total Current Assets | 17 | 20 | 23 | 30 | 32 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 3 | 3 | 3 | 3 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 1 |
Total Assets | 22 | 25 | 28 | 34 | 37 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 7 | 9 | 9 | 6 |
Current Portion Long-Term Debt | 0 | 2 | 4 | 2 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 4 | 11 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 7 | 7 |
Total Current Liabilities | 9 | 14 | 18 | 29 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 4 | 3 | 4 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 11 | 26 | 23 | 33 | 30 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 4 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 121 | 105 | 104 | 104 | 104 |
Retained Earnings | -110 | -110 | -100 | -103 | -97 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 11 | -2 | 5 | 1 | 7 |
Total Liabilities & Shareholder's Equity | 22 | 25 | 28 | 34 | 37 |
Total Common Equity | 11 | -5 | 5 | 1 | 7 |
Shares Outstanding | 5.00 | 5.00 | 1.50 | 1.30 | 1.30 |
Book Value Per Share | 2.18 | -1.08 | 3.19 | 0.80 | 5.52 |